Although we did not confirm all the side-effects against KAS-08, the low toxicity of KAS-08 in some type of immune cells such as THP-1 and PBMC (Figure 3c and Figure S4) and the minimal immune response without STING activation (Figure 3a) could provide an advantage in terms of a reduction in the potential side effects by targeting STING pathways in the tumor microenvironment. The gene discussed is STING1; the disease is neoplasm.